Tech Times of New York
SEE OTHER BRANDS

Hottest science and technology news from New York

Tech Times of New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.

Press releases published on July 8, 2025

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients 11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 …

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) ( …

Sanborn Geophysics Doubles Production, Launches Upgraded Product Line, and Prepares Move to Purpose-Built Facility

Sanborn Geophysics Doubles Production, Launches Upgraded Product Line, and Prepares Move to Purpose-Built Facility

COLORADO SPRINGS, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Sanborn Geophysics ULC, a subsidiary of The Sanborn Map Company, today announced a major step in its evolution from general geophysical solutions to a product-driven model capable of meeting …

Willis launches $200m facility to tackle global geopolitical uncertainty for cargo owners

Willis launches $200m facility to tackle global geopolitical uncertainty for cargo owners

LONDON, July 08, 2025 (GLOBE NEWSWIRE) -- Willis, a WTW business (NASDAQ: WTW), has launched ‘Undercover’, a new $200 million facility, combining coverage for a range of geopolitical exposures faced by cargo owners worldwide. Developed by Willis in a joint …

Calian Reinforces Support for Canadian Armed Forces with $250M Contract Amendment

Calian Reinforces Support for Canadian Armed Forces with $250M Contract Amendment

OTTAWA, Ontario, July 08, 2025 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, today announced a $250 million amendment to its …

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the …

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, …

Xtract One Selected by Mecklenburg County Public Schools to Enhance Building Security District-Wide

Xtract One Selected by Mecklenburg County Public Schools to Enhance Building Security District-Wide

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its Xtract One Gateway (“Gateway”) system has been selected by Mecklenburg County Public Schools, located …

Mercury Receives Two New Common Processing Architecture Production Awards

Mercury Receives Two New Common Processing Architecture Production Awards

ANDOVER, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing to the edge, today announced it received two new production awards in June totaling $36.9 …

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person …

Agios Appoints Dr. Jay Backstrom to Board of Directors

Agios Appoints Dr. Jay Backstrom to Board of Directors

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M. …

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel …

ROM: Golden Age Blasts Past 500,000 Pre-Registrations - Join the Buddy Boost Lottery for a Shot at Massive Crypto Prizes

ROM: Golden Age Blasts Past 500,000 Pre-Registrations - Join the Buddy Boost Lottery for a Shot at Massive Crypto Prizes

Singapore, July 08, 2025 (GLOBE NEWSWIRE) -- Big news: ROM: GoldenAge—the hottest upcoming blockchain strategy game—has just smashed through half a million pre-registrations on WEMIX PLAY! Yes, over 500,000 pre-registrations! Pre-register now and …

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline …

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences to Participate in Two Upcoming Investor Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …

Energous Reports Preliminary Record Quarterly Revenue, Achieves Lowest Net Loss in Ten Years, and Retires High-Interest Debt

Energous Reports Preliminary Record Quarterly Revenue, Achieves Lowest Net Loss in Ten Years, and Retires High-Interest Debt

SAN JOSE, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Energous Corporation d/b/a Energous Wireless Power Solutions (NASDAQ: WATT), a leader in over-the-air (OTA) wireless power networks, today announced preliminary results for its second quarter of 2025, …

 Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required prior to proceeding to pivotal clinical trials necessary …

Liquidity Services Announces Third Quarter Fiscal Year 2025 Earnings Conference Call

Liquidity Services Announces Third Quarter Fiscal Year 2025 Earnings Conference Call

BETHESDA, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Liquidity Services (NASDAQ:LQDT), a leading global commerce company powering the circular economy, today announced that it expects to report its third quarter fiscal year 2025 results prior to market open on …

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

- NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service